Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$116.8MCash on Hand
8.2mo Cash Runway
Follow NMRA by emailGet an email when NMRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NMRA, unsubscribe in one click. Privacy
📣 What NMRA Says Is Next
Second Half of 2026 · “NMRA-898 (M4 Positive Allosteric Modulator): Phase 1 Data Expected in Second Half of 2026 Neumora is conducting a MAD study with NMRA-898 in healthy volunteers and patients with stable schizophrenia and expects to report data from the study in the second half of 2026.”
Company press release, Aug 14, 2026 · SEC filing
Fourth Quarter of 2026 · “NMRA-511 (Vasopressin 1a Receptor Antagonist): On Track to Report Data from Multiple Ascending Dose (MAD) Expansion Cohort in Alzheimer’s Disease (AD) Agitation in Fourth Quarter of 2026 Neumora plans to report data from a MAD expansion cohort evaluating higher doses of NMRA-511 in healthy elderly participants in the fourth quarter of 2026 and to initiate a Phase 2 study with NMRA-511 in Alzheimer's disease agitation by the end of 2026.”
Company press release, Aug 14, 2026 · SEC filing
fourth quarter of 2026 · “The Company expects to submit an IND in the fourth quarter of 2026 and to initiate a Phase 1 study by the end of 2026.”
Company press release, Aug 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 16, 2026 ·
Earnings Reported a Q3 2026 net loss of $34.4 million versus $56.8 million a year earlier, with R&D expense of $22.6 million and cash of $85.7 million at September 30, 2026. Company is not providing updated runway guidance and says it will need substantial additional funding. Form 8-K · SEC filing · Press release
Oct 30, 2026 ·
Listing Received Nasdaq notice on October 26, 2026 for noncompliance with the $1.00 minimum bid price requirement. The company has until April 26, 2027 to regain compliance, requiring a closing bid of at least $1.00 for ten consecutive business days, and may consider a reverse stock split. Form 8-K · SEC filing
Aug 14, 2026 ·
Leadership Neumora reported Q2 2026 net loss of $43.1 million, down from $52.7 million, with $116.8 million in cash expected to fund operations into Q3 2027. Joshua Pinto, Ph.D., became CEO and a director, and Paul L. Berns became Executive Chair. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2026 · Phase 3 · Results Expected · Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder Registry primary completion date, not a results date
May 2026 · Phase 3 · Results Expected · Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder Registry primary completion date, not a results date
Nov 2025 · Phase 1 · Results Expected · Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease Registry primary completion date, not a results date
Apr 2025 · Phase 2 · Results Expected · To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder. Registry primary completion date, not a results date
Dec 2024 · Phase 3 · Results Expected · Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder Registry primary completion date, not a results date
Apr 2022 · Phase 2 · Results Expected · Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
NMRA holds $116.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $43M/quarter from operations,
an estimated runway of 8.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:77 · High
Cash runway 6 months +30
ATM program on file since Oct 2024 +15
Shelf registration (S-3ASR, Oct 2024) +10
Going-concern doubt in the latest 10-Q +15The mitigating effect of the Company’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or…10-Q, Nov 2026
Share count 188,694,709 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NMRA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NMRA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.